Adjunctive Rifampin for the Treatment of Prosthetic Valve Endocarditis Due to S. Aureus
Recruiting now · Phase 3
Conditions studied: Staphylococcus Aureus Endocarditis, Prosthetic Valve Endocarditis
In brief
This is a sub-study of the S. aureus Network Adaptive Platform (SNAP) trial (NCT05137119) wherein we will evaluate whether not giving rifampin in patients with probable or definite prosthetic valve endocarditis due to S. aureus is non-inferior to giving rifampin.
Key facts
- Study ID
- NCT07253688
- Run by
- Todd C. Lee MD MPH FIDSA
- People needed
- 330
- Starts
- 2025-11-10
- Expected to finish
- 2030-07-01
- Last updated by the study team
- 2025-12-10
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Probable or definite prosthetic valve endocarditis involving the tricuspid, pulmonic, mitral and/or aortic valves by the 2023 Duke-ISCVID Criteria (including Cardiac PET evidence if applicable);
- Patient or healthcare proxy provide informed consent.
You may not qualify if…
- Death deemed imminent and inevitable within days or patient will be receiving palliative care and has prognosis < 90 days according to the treating team;
- Patient requires intensive care but has a do not resuscitate order precluding transfer;
- Polymicrobial bacteremia (not including skin commensals or other recognized contaminant);
- Organism tests as rifampin resistant;
- History of hypersensitivity/anaphylaxis or severe adverse reaction to rifampin;
- Category X or other important drug-drug interaction with rifampin which cannot be safely mitigated [with as-needed consultation from experts from pharmacy and/or internal medicine/geriatrics for potential deprescribing];
- Child Pugh Class C cirrhosis;
- Clinician deems rifampin to be mandatory;
- Patient has already received >3 days of rifampin at time of screening or >10 days of total therapy
- Pregnancy or breast feeding
- Administrative exclusions:
- No reliable means of outpatient contact (telephone/email/text);
- Previously enrolled;
- Prior S. aureus bacteremia within the preceding 180 days
Where it is running
- McGill University Health Centre (Royal Victoria Hospital and Montreal General Hospital) — Montreal, Quebec, Canada (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.